Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema

NCT04739059 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT04739059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04739059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema
Lead sponsor
CSL Behring
Phase
Phase 3
Overall status
Completed
Start date
March 29, 2021
Completion date
November 21, 2025
Enrollment
171 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema